Use of Medicines Changing the Face of Abortion

Winikoff, Beverly; Sheldon, Wendy R.

doi:10.1363/3816412

Cited by 57 publications

(41 citation statements)

References 23 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As it can be obtained independently of husband or provider, misoprostol has reduced women's dependence on their families and providers, and thereby provided them with greater autonomy regarding their reproductive needs 29. Even where patients sought the drug from a trained provider, misoprostol created a separation between the provider and the actual abortion procedure.…”

Section: Discussionmentioning

confidence: 99%

Abortion and fertility control in Pakistan: the role of misoprostol

Chahal

Mumtaz

2017

J Fam Plann Reprod Health Care

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Abortion and fertility control in Pakistan: the role of misoprostol

Chahal

Mumtaz

2017

J Fam Plann Reprod Health Care

View full text Add to dashboard Cite

show abstract

“…Marketed as Cytotec (Pfizer, New York, NY, USA), misoprostol is an effective and progressively popular option for self‐administration, especially in low‐resource countries . Mifepristone, followed by a prostaglandin (such as misoprostol), is considered the gold standard for medical abortion . A regimen of 200 mg mifepristone and 800 μg buccal or vaginal misoprostol is 95%–98% effective .…”

Section: Introductionmentioning

confidence: 99%

Availability and prescription of misoprostol for medical abortion in community pharmacies and associated factors in Accra, Ghana

Ganle

Busia

Maya

2018

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Objective To assess misoprostol availability at community pharmacies and determine factors affecting misoprostol prescription for medical abortion. Methods A cross‐sectional quantitative survey of randomly sampled community pharmacies and their corresponding pharmacists/pharmacy workers was conducted in the city of Accra, Ghana. Structured questionnaires were administered to collect data between May 1 and July 28, 2016. Descriptive statistics (frequencies and proportions) and bivariate and logistic regression analysis were used to analyze the data. Results Of the 165 community pharmacies surveyed, approximately half (83 [50.3%]) stocked misoprostol. Availability of misoprostol however decreased when moving from first class to third class residential areas. 44 (26.7%) of the respondents had prescribed the drug at some time for medical abortion, but 140 (84.6%) indicated they would not prescribe the drug for medical abortion in future. Factors that significantly predicted misoprostol prescription for medical abortion included sex of the pharmacist/pharmacy worker, demand, and availability of misoprostol. Conclusions Demand for misoprostol for medical abortion was found to be high but only half of community pharmacies stocked it, and most pharmacy workers did not wish to prescribe the drug. If community pharmacies are to effectively contribute to expanding access to safe abortion services in Ghana, the disparity between misoprostol provision and demand needs to be addressed.

show abstract

“…The most important change has been in the increased availability of misoprostol, a drug that can be used to terminate a pregnancy with a clinical effectiveness rate of approximately 85%, when used correctly . The current availability and use of misoprostol varies across countries, but overall, this trend is likely to have reduced the severity of complications as women switch from more damaging methods to using this medication . On the other hand, based on some evidence showing no decline and some increases in the rate of women treated in facilities (number treated per 1000 women of reproductive age), it appears that at least in the short run, women often do not have the information they need to use the medication correctly and/or that the drug that they are obtaining is substandard .…”

Section: Introductionmentioning

confidence: 99%

Facility‐based treatment for medical complications resulting from unsafe pregnancy termination in the developing world, 2012: a review of evidence from 26 countries

Singh

Maddow‐Zimet

2015

BJOG

167

136

View full text Add to dashboard Cite

With changing conditions affecting receipt of postabortion care, an updated estimate of the incidence of treatment for complications from unsafe pregnancy termination is needed to inform policies and programmes. National estimates of facility-based treatment for complications in 26 countries form the basis for estimating treatment rates in the developing world. An estimated seven million women were treated in the developing world for complications from unsafe pregnancy termination in 2012, a rate of 6.9 per 1000 women aged 15–44 years. Regionally, rates ranged from 5.3 in Latin America and the Caribbean to 8.2 in Asia. Results inform policies to improve women’s health.

show abstract

Use of Medicines Changing the Face of Abortion

Cited by 57 publications

References 23 publications

Abortion and fertility control in Pakistan: the role of misoprostol

Abortion and fertility control in Pakistan: the role of misoprostol

Availability and prescription of misoprostol for medical abortion in community pharmacies and associated factors in Accra, Ghana

Facility‐based treatment for medical complications resulting from unsafe pregnancy termination in the developing world, 2012: a review of evidence from 26 countries

Contact Info

Product

Resources

About